Tetraphase Pharmaceuticals (NASDAQ:TTPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Saturday, January 6th.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
Several other equities research analysts have also issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, December 5th. Stifel Nicolaus reissued a “buy” rating and set a $13.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, September 12th. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Sunday, September 17th. BMO Capital Markets increased their target price on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 4th. Finally, ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $15.15.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, meeting the consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The company had revenue of $4.10 million for the quarter, compared to analyst estimates of $1.59 million. During the same period in the prior year, the company earned ($0.58) earnings per share. The firm’s revenue was up 355.6% on a year-over-year basis. equities research analysts anticipate that Tetraphase Pharmaceuticals will post -2.88 EPS for the current year.
In other news, Director L Patrick Gage purchased 3,880 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the acquisition, the director now directly owns 38,880 shares of the company’s stock, valued at $250,776. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total transaction of $52,762.50. Following the sale, the insider now owns 8,750 shares of the company’s stock, valued at approximately $52,762.50. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the stock. California Public Employees Retirement System increased its holdings in Tetraphase Pharmaceuticals by 2.0% in the 2nd quarter. California Public Employees Retirement System now owns 242,200 shares of the biopharmaceutical company’s stock valued at $1,727,000 after purchasing an additional 4,800 shares during the last quarter. EcoR1 Capital LLC acquired a new stake in Tetraphase Pharmaceuticals in the 2nd quarter valued at approximately $4,516,000. Northern Trust Corp increased its holdings in Tetraphase Pharmaceuticals by 4.8% in the 2nd quarter. Northern Trust Corp now owns 886,765 shares of the biopharmaceutical company’s stock valued at $6,323,000 after purchasing an additional 40,668 shares during the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Tetraphase Pharmaceuticals by 95.5% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 393,000 shares of the biopharmaceutical company’s stock valued at $2,688,000 after purchasing an additional 192,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Tetraphase Pharmaceuticals by 73.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,101,255 shares of the biopharmaceutical company’s stock valued at $7,853,000 after purchasing an additional 466,955 shares during the last quarter. Hedge funds and other institutional investors own 58.15% of the company’s stock.
WARNING: This article was first published by BBNS and is the property of of BBNS. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://baseballnewssource.com/markets/tetraphase-pharmaceuticals-ttph-downgraded-by-zacks-investment-research-to-sell/1823289.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.